Published in ISRN Oncol on April 11, 2013
Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med (1998) 25.41
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12
Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol (2006) 20.28
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res (2004) 16.51
G1 phase progression: cycling on cue. Cell (1994) 11.62
Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell (1994) 9.25
Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer (2004) 9.24
Cyclin E and survival in patients with breast cancer. N Engl J Med (2002) 6.44
Reporting recommendations for tumor marker prognostic studies. J Clin Oncol (2005) 6.31
Prognostic markers in triple-negative breast cancer. Cancer (2007) 6.28
Proliferation marker Ki-67 in early breast cancer. J Clin Oncol (2005) 4.74
Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin (2006) 4.73
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer (2007) 4.44
Racial differences in survival from breast cancer. Results of the National Cancer Institute Black/White Cancer Survival Study. JAMA (1994) 4.35
Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst (1994) 4.28
Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med (1997) 4.21
Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene (1995) 3.96
The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res (2004) 3.66
High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer (2005) 3.07
Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol (2009) 2.88
Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35. Cancer (2003) 2.84
A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res (2005) 2.65
Trends in breast cancer by race and ethnicity. CA Cancer J Clin (2004) 2.19
Breast cancer in African-American women: differences in tumor biology from European-American women. Cancer Res (2006) 2.18
Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women. Breast Cancer Res Treat (2012) 2.05
Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer (2004) 1.97
The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res (2000) 1.81
The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers. J Pathol (2010) 1.79
Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer (2006) 1.76
Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. Int J Cancer (2007) 1.53
Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer. BMC Clin Pathol (2011) 1.46
Racial differences in the expression of cell cycle-regulatory proteins in breast carcinoma. Cancer (2004) 1.36
E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. Histopathology (2005) 1.17
Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens. Histopathology (2010) 1.13
G1-S transition defects occur in most breast cancers and predict outcome. Breast Cancer Res Treat (1999) 1.10
Loss of CD59 expression in breast tumours correlates with poor survival. J Pathol (2003) 1.07
Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. Int J Cancer (2006) 1.07
Protein expression profile and prevalence pattern of the molecular classes of breast cancer--a Saudi population based study. BMC Cancer (2010) 1.04
Ethnic differences in risk and prognostic factors for breast cancer. Cancer (1995) 0.99
Growth fraction as a predictor of response to chemotherapy in node-negative breast cancer. Int J Cancer (2010) 0.92
Pattern of breast cancer among white-American, African-American, and nonimmigrant west-African women. J Natl Med Assoc (1998) 0.92
Ki-67, p53, ER receptors, ploidy and S phase as long-term prognostic factors in T1 node-negative breast cancer. Tumour Biol (2006) 0.90
The importance of prognostic factors in premenopausal women with breast cancer. Anticancer Res (2007) 0.87
High estrogen receptor expression and low Ki67 expression are associated with improved time to progression during first-line endocrine therapy with aromatase inhibitors in breast cancer. Int J Clin Oncol (2011) 0.85
[Molecular subtypes of breast cancer: prognostic implications and clinical and immunohistochemical characteristics]. An Sist Sanit Navar (2011) 0.79
The proteasome controls the expression of a proliferation-associated nuclear antigen Ki-67. J Cell Biochem (2000) 0.79
Relationships between immunophenotype, Ki-67 index, microvascular density, Ep-CAM/P-cadherin, and MMP-2 expression in early-stage invasive ductal breast cancer. Appl Immunohistochem Mol Morphol (2012) 0.77
MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol (2007) 6.41
Prognostic markers in triple-negative breast cancer. Cancer (2007) 6.28
Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol (2011) 6.13
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature (2012) 5.84
Basal-like breast cancer: a critical review. J Clin Oncol (2008) 5.64
High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol (2007) 4.70
An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol (2007) 4.33
Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol (2004) 3.80
Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol (2007) 3.55
Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol (2010) 3.27
High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer (2005) 3.07
Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res (2009) 2.91
Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget (2010) 2.64
Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. Nat Med (2011) 2.49
Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol (2010) 2.42
Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res (2010) 2.33
A consensus prognostic gene expression classifier for ER positive breast cancer. Genome Biol (2006) 2.17
Triple-negative/basal-like breast cancer: review. Pathology (2009) 2.17
Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res (2006) 2.16
Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol (2008) 2.13
ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium. EMBO Mol Med (2011) 2.07
Further evidence that E-cadherin is not a tumour suppressor gene in invasive ductal carcinoma of the breast: an immunohistochemical study. Histopathology (2013) 2.05
Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol (2005) 2.03
High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol (2007) 2.00
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res (2013) 1.92
Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. Am J Surg Pathol (2013) 1.83
Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol (2005) 1.82
IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res (2008) 1.80
The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers. J Pathol (2010) 1.79
FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res (2007) 1.78
Tubular carcinoma of the breast: further evidence to support its excellent prognosis. J Clin Oncol (2009) 1.77
Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer (2006) 1.76
Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysis. Am J Surg Pathol (2005) 1.70
Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res (2009) 1.63
Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast. Am J Surg Pathol (2010) 1.63
Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res (2008) 1.58
Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer (2006) 1.52
The emerging role of the LIV-1 subfamily of zinc transporters in breast cancer. Mol Med (2007) 1.51
The ubiquitin-binding protein p62 is expressed in breast cancers showing features of aggressive disease. Endocr Relat Cancer (2007) 1.49
Audit of performance of needle core biopsy diagnoses of screen detected breast lesions. Eur J Cancer (2008) 1.48
Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur J Cancer (2007) 1.46
Combinatorial biomarker expression in breast cancer. Breast Cancer Res Treat (2010) 1.43
Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancer. Breast Cancer Res (2009) 1.42
Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family. Am J Surg Pathol (2008) 1.41
Expression of BRCA1 protein in breast cancer and its prognostic significance. Hum Pathol (2008) 1.40
Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast. Breast Cancer Res Treat (2007) 1.39
Improved methods of detection of lymphovascular invasion demonstrate that it is the predominant method of vascular invasion in breast cancer and has important clinical consequences. Am J Surg Pathol (2007) 1.38
Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status. Breast Cancer Res Treat (2008) 1.33
LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcome. Breast Cancer Res Treat (2011) 1.33
BEX2 is overexpressed in a subset of primary breast cancers and mediates nerve growth factor/nuclear factor-kappaB inhibition of apoptosis in breast cancer cell lines. Cancer Res (2007) 1.33
An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer. Breast Cancer Res Treat (2010) 1.31
Are triple-negative tumours and basal-like breast cancer synonymous? Breast Cancer Res (2007) 1.29
The diagnosis and management of pre-invasive breast disease: ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH)--current definitions and classification. Breast Cancer Res (2003) 1.27
The prognostic significance of lymphovascular invasion in invasive breast carcinoma. Cancer (2011) 1.27
The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype. Breast Cancer Res Treat (2009) 1.27
Do primary mammary osteosarcoma and chondrosarcoma exist? A review of a large multi-institutional series of malignant matrix-producing breast tumours. Breast (2012) 1.27
An immunohistochemical study of metaplastic spindle cell carcinoma, phyllodes tumor and fibromatosis of the breast. Hum Pathol (2003) 1.26
Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer (2005) 1.25
Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. Eur J Cancer (2008) 1.24
Correlation of histologic prognostic factors in core biopsies and therapeutic excisions of invasive breast carcinoma. Am J Surg Pathol (2003) 1.24
CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome. Breast Cancer Res Treat (2007) 1.22